CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans Oct 22, 2026
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans Oct 22, 2026
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells Oct 16, 2026
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer Oct 14, 2026
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib Oct 7, 2026
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results Sep 29, 2026
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 Sep 22, 2026
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. Sep 16, 2026
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 Sep 9, 2026
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit Aug 27, 2026
